Survival Advantage From Higher-Dose Radiation Therapy for Clinically Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials
We evaluated the effect of external-beam radiation therapy on disease-specific survival (death from causes related to prostate cancer) and overall survival in men with clinically localized prostate cancer. From 1975 to 1992, 1,465 men with clinically localized prostate cancer received radiation ther...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2000-07, Vol.18 (14), p.2740-2746 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2746 |
|---|---|
| container_issue | 14 |
| container_start_page | 2740 |
| container_title | Journal of clinical oncology |
| container_volume | 18 |
| creator | VALICENTI, R JIANDONG LU PILEPICH, M ASBELL, S GRIGNON, D |
| description | We evaluated the effect of external-beam radiation therapy on disease-specific survival (death from causes related to prostate cancer) and overall survival in men with clinically localized prostate cancer.
From 1975 to 1992, 1,465 men with clinically localized prostate cancer received radiation therapy on four Radiation Therapy Oncology Group phase III randomized trials and were pooled for this analysis. No one received androgen-deprivation therapy with his initial treatment. All original histology had central pathologic review for grading using the Gleason classification system. Total delivered radiation dose ranged from 60 to 78 Gy (median, 68.4 Gy). The median follow-up time was 8 years.
A Cox regression model revealed that Gleason score was an independent predictor of disease-specific survival and overall survival. The 10-year disease-specific survival rates by Gleason score were as follows: score of 2 through 5, 85%; score of 6, 79%; score of 7, 62%; and score of 8 through 10, 43%. Stratifying outcome by this important prognostic factor revealed that higher radiation dose was a significant predictor for improved disease-specific survival and overall survival only for those patients whose cancers had Gleason scores of 8 through 10 (P |
| doi_str_mv | 10.1200/JCO.2000.18.14.2740 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71233316</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71233316</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-f1480997bbd5914ab5527b812f208a311b95a47f3d0315203ea468cada28bea63</originalsourceid><addsrcrecordid>eNptkc2O0zAUhS0EYjoDT4CEvEDMKsV_qZ3lKDAzoEpFUCR21k3itB4lccdOisp78L7cqpWYBaura333WOccQt5wNueCsQ9fytUcJ25mztVcaMWekRnPhc60zvPnZMa0FBk38ucFuUzpgTGujMxfkgvOTKGMVjPy5_sU934PHb1p9jCMsHH0Noae3vvN1sXsY0iOfoPGw-jDQNf4BrsDbUOkZecHX0PXHegy4PS_XUO_xpBGGB0tYahdpOvocGso3o7b_ymthjp0YXOgdzFMO-Q9dOkVedHicK_P84r8uP20Lu-z5eruc3mzzGq5EGPWoh9WFLqqmrzgCqoczVeGi1YwA5LzqshB6VY2TGIuTDpQC1NDA8JUDhbyirw_6e5ieJxcGm3vU-26DgYXpmQ1F1JKfgTlCazRX4qutbvoe4gHy5k9tmGxDXtsw3JjubLHNvDq7Vl-qnrXPLk5xY_AuzMACRNsI4bm0z9OKY32ELs-YVss5ZePzqYec0dVYR_q8OTHv9p6oVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71233316</pqid></control><display><type>article</type><title>Survival Advantage From Higher-Dose Radiation Therapy for Clinically Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><creator>VALICENTI, R ; JIANDONG LU ; PILEPICH, M ; ASBELL, S ; GRIGNON, D</creator><creatorcontrib>VALICENTI, R ; JIANDONG LU ; PILEPICH, M ; ASBELL, S ; GRIGNON, D</creatorcontrib><description>We evaluated the effect of external-beam radiation therapy on disease-specific survival (death from causes related to prostate cancer) and overall survival in men with clinically localized prostate cancer.
From 1975 to 1992, 1,465 men with clinically localized prostate cancer received radiation therapy on four Radiation Therapy Oncology Group phase III randomized trials and were pooled for this analysis. No one received androgen-deprivation therapy with his initial treatment. All original histology had central pathologic review for grading using the Gleason classification system. Total delivered radiation dose ranged from 60 to 78 Gy (median, 68.4 Gy). The median follow-up time was 8 years.
A Cox regression model revealed that Gleason score was an independent predictor of disease-specific survival and overall survival. The 10-year disease-specific survival rates by Gleason score were as follows: score of 2 through 5, 85%; score of 6, 79%; score of 7, 62%; and score of 8 through 10, 43%. Stratifying outcome by this important prognostic factor revealed that higher radiation dose was a significant predictor for improved disease-specific survival and overall survival only for those patients whose cancers had Gleason scores of 8 through 10 (P <.05). After adjusting for clinical T stage, nodal status, and age, treating with a higher radiation dose was associated with a 29% lower relative risk of death from prostate cancer and 27% reduced mortality rate (P <.05).
These data demonstrate that higher-dose radiation therapy can significantly reduce the risk of dying from prostate cancer in men with clinically localized disease. This survival benefit is restricted to men with poorly differentiated cancers.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2000.18.14.2740</identifier><identifier>PMID: 10894874</identifier><language>eng</language><publisher>Baltimore, MD: American Society of Clinical Oncology</publisher><subject>Aged ; Aged, 80 and over ; Biological and medical sciences ; Clinical Trials, Phase III as Topic ; Disease Progression ; Diseases of the urinary system ; Humans ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Nephrology. Urinary tract diseases ; Proportional Hazards Models ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - radiotherapy ; Radiotherapy Dosage ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Randomized Controlled Trials as Topic ; Survival Analysis ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>Journal of clinical oncology, 2000-07, Vol.18 (14), p.2740-2746</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-f1480997bbd5914ab5527b812f208a311b95a47f3d0315203ea468cada28bea63</citedby><cites>FETCH-LOGICAL-c362t-f1480997bbd5914ab5527b812f208a311b95a47f3d0315203ea468cada28bea63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1447997$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10894874$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VALICENTI, R</creatorcontrib><creatorcontrib>JIANDONG LU</creatorcontrib><creatorcontrib>PILEPICH, M</creatorcontrib><creatorcontrib>ASBELL, S</creatorcontrib><creatorcontrib>GRIGNON, D</creatorcontrib><title>Survival Advantage From Higher-Dose Radiation Therapy for Clinically Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>We evaluated the effect of external-beam radiation therapy on disease-specific survival (death from causes related to prostate cancer) and overall survival in men with clinically localized prostate cancer.
From 1975 to 1992, 1,465 men with clinically localized prostate cancer received radiation therapy on four Radiation Therapy Oncology Group phase III randomized trials and were pooled for this analysis. No one received androgen-deprivation therapy with his initial treatment. All original histology had central pathologic review for grading using the Gleason classification system. Total delivered radiation dose ranged from 60 to 78 Gy (median, 68.4 Gy). The median follow-up time was 8 years.
A Cox regression model revealed that Gleason score was an independent predictor of disease-specific survival and overall survival. The 10-year disease-specific survival rates by Gleason score were as follows: score of 2 through 5, 85%; score of 6, 79%; score of 7, 62%; and score of 8 through 10, 43%. Stratifying outcome by this important prognostic factor revealed that higher radiation dose was a significant predictor for improved disease-specific survival and overall survival only for those patients whose cancers had Gleason scores of 8 through 10 (P <.05). After adjusting for clinical T stage, nodal status, and age, treating with a higher radiation dose was associated with a 29% lower relative risk of death from prostate cancer and 27% reduced mortality rate (P <.05).
These data demonstrate that higher-dose radiation therapy can significantly reduce the risk of dying from prostate cancer in men with clinically localized disease. This survival benefit is restricted to men with poorly differentiated cancers.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Disease Progression</subject><subject>Diseases of the urinary system</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Proportional Hazards Models</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Survival Analysis</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkc2O0zAUhS0EYjoDT4CEvEDMKsV_qZ3lKDAzoEpFUCR21k3itB4lccdOisp78L7cqpWYBaura333WOccQt5wNueCsQ9fytUcJ25mztVcaMWekRnPhc60zvPnZMa0FBk38ucFuUzpgTGujMxfkgvOTKGMVjPy5_sU934PHb1p9jCMsHH0Noae3vvN1sXsY0iOfoPGw-jDQNf4BrsDbUOkZecHX0PXHegy4PS_XUO_xpBGGB0tYahdpOvocGso3o7b_ymthjp0YXOgdzFMO-Q9dOkVedHicK_P84r8uP20Lu-z5eruc3mzzGq5EGPWoh9WFLqqmrzgCqoczVeGi1YwA5LzqshB6VY2TGIuTDpQC1NDA8JUDhbyirw_6e5ieJxcGm3vU-26DgYXpmQ1F1JKfgTlCazRX4qutbvoe4gHy5k9tmGxDXtsw3JjubLHNvDq7Vl-qnrXPLk5xY_AuzMACRNsI4bm0z9OKY32ELs-YVss5ZePzqYec0dVYR_q8OTHv9p6oVg</recordid><startdate>20000701</startdate><enddate>20000701</enddate><creator>VALICENTI, R</creator><creator>JIANDONG LU</creator><creator>PILEPICH, M</creator><creator>ASBELL, S</creator><creator>GRIGNON, D</creator><general>American Society of Clinical Oncology</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000701</creationdate><title>Survival Advantage From Higher-Dose Radiation Therapy for Clinically Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials</title><author>VALICENTI, R ; JIANDONG LU ; PILEPICH, M ; ASBELL, S ; GRIGNON, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-f1480997bbd5914ab5527b812f208a311b95a47f3d0315203ea468cada28bea63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Disease Progression</topic><topic>Diseases of the urinary system</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Proportional Hazards Models</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Survival Analysis</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VALICENTI, R</creatorcontrib><creatorcontrib>JIANDONG LU</creatorcontrib><creatorcontrib>PILEPICH, M</creatorcontrib><creatorcontrib>ASBELL, S</creatorcontrib><creatorcontrib>GRIGNON, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VALICENTI, R</au><au>JIANDONG LU</au><au>PILEPICH, M</au><au>ASBELL, S</au><au>GRIGNON, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival Advantage From Higher-Dose Radiation Therapy for Clinically Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2000-07-01</date><risdate>2000</risdate><volume>18</volume><issue>14</issue><spage>2740</spage><epage>2746</epage><pages>2740-2746</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>We evaluated the effect of external-beam radiation therapy on disease-specific survival (death from causes related to prostate cancer) and overall survival in men with clinically localized prostate cancer.
From 1975 to 1992, 1,465 men with clinically localized prostate cancer received radiation therapy on four Radiation Therapy Oncology Group phase III randomized trials and were pooled for this analysis. No one received androgen-deprivation therapy with his initial treatment. All original histology had central pathologic review for grading using the Gleason classification system. Total delivered radiation dose ranged from 60 to 78 Gy (median, 68.4 Gy). The median follow-up time was 8 years.
A Cox regression model revealed that Gleason score was an independent predictor of disease-specific survival and overall survival. The 10-year disease-specific survival rates by Gleason score were as follows: score of 2 through 5, 85%; score of 6, 79%; score of 7, 62%; and score of 8 through 10, 43%. Stratifying outcome by this important prognostic factor revealed that higher radiation dose was a significant predictor for improved disease-specific survival and overall survival only for those patients whose cancers had Gleason scores of 8 through 10 (P <.05). After adjusting for clinical T stage, nodal status, and age, treating with a higher radiation dose was associated with a 29% lower relative risk of death from prostate cancer and 27% reduced mortality rate (P <.05).
These data demonstrate that higher-dose radiation therapy can significantly reduce the risk of dying from prostate cancer in men with clinically localized disease. This survival benefit is restricted to men with poorly differentiated cancers.</abstract><cop>Baltimore, MD</cop><pub>American Society of Clinical Oncology</pub><pmid>10894874</pmid><doi>10.1200/JCO.2000.18.14.2740</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2000-07, Vol.18 (14), p.2740-2746 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71233316 |
| source | MEDLINE; Journals@Ovid Ovid Autoload |
| subjects | Aged Aged, 80 and over Biological and medical sciences Clinical Trials, Phase III as Topic Disease Progression Diseases of the urinary system Humans Male Medical sciences Middle Aged Multivariate Analysis Neoplasm Staging Nephrology. Urinary tract diseases Proportional Hazards Models Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Radiotherapy Dosage Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Randomized Controlled Trials as Topic Survival Analysis Tumors of the urinary system Urinary tract. Prostate gland |
| title | Survival Advantage From Higher-Dose Radiation Therapy for Clinically Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A47%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20Advantage%20From%20Higher-Dose%20Radiation%20Therapy%20for%20Clinically%20Localized%20Prostate%20Cancer%20Treated%20on%20the%20Radiation%20Therapy%20Oncology%20Group%20Trials&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=VALICENTI,%20R&rft.date=2000-07-01&rft.volume=18&rft.issue=14&rft.spage=2740&rft.epage=2746&rft.pages=2740-2746&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2000.18.14.2740&rft_dat=%3Cproquest_cross%3E71233316%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71233316&rft_id=info:pmid/10894874&rfr_iscdi=true |